Ergothioneine (EGT) was discovered by Charles Tanret in 1909, whilst investigating the ergot fungus, Claviceps purpurea. It is a naturally occurring, sulfur-containing amino acid, and is known to be synthesized only by non-yeast fungi, and certain bacteria. Yet despite the inability to be synthesized by human being, ergothioneine is found in the entire human body, with the highest levels found in kidneys, liver, red blood cells, and semen. While a certain function still needs to be clarified, ergothioneine may be important to human health due to the prevalence of a special transporter in many tissues (Journal of Functional Foods, Volume 77, February 2021, 104326). Studies have highlighted its antioxidant abilities in vitro, and possible cytoprotective capabilities in vivo (Scientific Reports volume 8, Article number: 1601 (2018)). Since human cannot synthesize ergothioneine, it can only be acquired through diet. Studies in animals and humans have found no toxicity or adverse effects to be associated with ergothioneine administration, even at high doses, and recently, ergothioneine (Tetrahedron, Paris, France) has attained European Food Safety Authority approval in the European Union and is generally recognized as a safe supplement by the Food and Drug Administration in the US (GRAS notice No. 734) (FEBS Letters 592 (2018) 3357-3366).
Thus, ergothioneine is a potentially useful dietary supplement. Present methods for preparation of ergothioneine includes extraction from natural sources, biosynthesis pathway and chemical synthesis, for example, Chinese patent CN 106831597 B discloses a method for preparing ergothioneine from mushroom; U.S. Pat. Nos. 10,544,437 B2 and 10,167,490 B2 disclose methods for ergothioneine biosynthesis; and U.S. Pat. Nos. 5,438,151 A; 7,767,826 B2; 8,399,500 B2; 9,908,854 B2; and 9,428,463 B1 disclose methods for chemical synthesis of ergothioneine.
The present invention provides a process for chemical synthesis of ergothioneine. Interestingly, the non-natural enantiomers D-ergothioneine can also be easily obtained from D-histidine by using the present method. Hence, each component of the composition can be either a pure optical isomer (e.g., L-form or D-form), or a mixture of both isomers depending on the choice of the starting compounds, which can be present in pure L- or D-form, or as mixtures thereof. Moreover, this present process greatly reduces the total number of synthetic steps for preparing EGT, and improves the overall yield, thereby lowering the cost. Other than that, this process disclosed in this application can also be economically and conveniently used for industrial production of ergothioneine.
This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter.
One aspect of the invention provides a novel process for chemical synthesis of different optical isomers of ergothioneine, or a physiologically acceptable salt thereof, comprising the following successive steps:
In some embodiments, the compound (II) has the following structure:
Examples of R include
In some embodiments, the compound (III) has the following structure:
Examples of R include
In some embodiments, the compound (IV) has the following structure:
In some embodiments, the compound (V) has the following structure:
In some embodiments, in step (a),
In some preferred embodiments, in step (a), the protective reagent 1 is dimethyldichlorosilane, the protective reagent 2 is triphenylchloromethane, the first solvent is dichloromethane, and the base is triethylamine or pyridine.
In some embodiments, in step (a), the molar ratio of the base and the compound (I) ranges from 1:1 to 3:1; molar ratio of the protective reagent 1 and the compound (I) ranges from 1:1 to 3:1; molar ratio of the protective reagent 2 and the compound (I) ranges from 1:1 to 3:1; and the reaction temperature ranges from 0-80° C., more preferably, 10-40° C.
In some embodiments, in step (b), the alkylation reagent is selected from the group consisting of dimethyl sulfate, methyl iodide, methyl bromide or methyl chloride; and the second solvent is selected from the group consisting of acetonitrile, methanol, ethanol or water.
Preferably, in step (b), the alkylation reagent is dimethyl sulfate, and the second solvent is methanol.
In some embodiments, in step (b), the molar ratio of the alkylation reagent and the compound (II) ranges from 1:1 to 3:1; and the reaction temperature ranges from 20 to 100° C., more preferably, 20-30° C.
In some embodiments, in step (c), the third solvent is selected from the group consisting of acetonitrile, methanol, ethanol or water; the acid is selected from the group consisting of hydrochloric acid, sulfuric acid, trifluoroacetic acid, or trifluoromethanesulfonic acid.
Preferably, in step (c), the third solvent is water, and the acid is hydrochloric acid.
In some embodiments, in step (c), molar ratio of the acid and compound (III) ranges from 1:1 to 10:1, preferably from 2:1 to 5:1; and the reaction temperature ranges from 20 to 80° C., or preferably 70-80° C.
In some embodiments, in step (d), the fourth solvent is selected from the group consisting of water, methanol and ethanol; the halogenated reagent is selected from the group consisting of bromine, dibromohydantoin, imidazolidinedione, bromosuccinimide, iodosuccinimide, and chlorosuccinimide; and the cleavage reagent is selected from the group consisting of cysteamine, sodium thiosulfate, ammonium thiocyanate and mercaptopropionic acid.
Preferably, in step (d), the fourth solvent is water, the halogenated reagent is bromosuccinimide, and the cleavage reagent is sodium thiosulfate.
In some embodiments, in step (d), the molar ratio of the vulcanization reagent and the compound (IV) ranges from 1:1 to 10:1, or preferably from 3:1 to 5:1.
In some embodiments, in step (d), the molar ratio of the cleavage reagent and compound (IV) ranges from 1 to 5:1, preferably from 2:1 to 3:1; and the reaction temperature ranges from 0 to 100° C., or preferably 70 to 90° C.
In some embodiments, in step (d), the post-treatment process comprises at least one step selected from the group consisting of filtration, decolorization, electrodialysis, concentration, ion-exchange chromatography and recrystallization in a recrystallization reagent.
Preferably, in step (d), the post-treatment process is recrystallization.
Examples of the recrystallization reagent includes isopropanol, ethanol, methanol, water, or any combination or mixture thereof.
Another aspect of the invention provides an antioxidant composition, comprising a mixture of L-ergothioneine and D-ergothioneine.
In some embodiments, the mixture comprises less than or equal to 100% (e.g., 30-80% or 45-55%) by enantiomeric equivalents of the L-ergothioneine and greater than or equal to 0% (e.g., 20-70% or 45-55%) from by enantiomeric equivalents of the D-ergothioneine.
In some embodiments, the composition is prepared in a form of nutritional, drinking, cosmetic or pharmaceutical composition, for use in a food, drink, nutritional, cosmetic or pharmaceutical products.
In some embodiments, the composition is administrated in a form of capsule, tablet, powder, suspension, solutions, drops, granules, liquids, syrups, functionalized foods, beverages, toothpastes, sublingual articles, food product, food additive, candy, sucker, pastille, food supplement, and suppository.
Reference will now be made in detail to the preferred embodiments of the invention, examples of which are further illustrated. While the invention will be described in conjunction with the preferred embodiments, it will be understood that they are not intended to limit the invention to these embodiments. On the contrary, the invention is intended to cover alternatives, modifications, and equivalents, which may be included within the spirit and scope of the invention as defined by the claims. Furthermore, in the detailed description of the present invention, numerous specific details are set forth in order to provide a thorough understanding of the present invention. However, it will be obvious to one of ordinary skill in the art that the present invention may be practiced without these specific details. In other instances, well-known methods, procedures, components, and other features have not been described in detail as not to unnecessarily obscure aspects of the present invention.
One aspect of the present invention is directed to a novel process for chemical synthesis of ergothioneine, resulting in high product yield without any racemized product. This process can produce ergothioneine either in a pure optical form (e.g., L-form or D-form), or a mixture of both forms in any ratio as needed. Surprisingly, it can directly provide ergothioneine of high-quality standard, thus obviating the need for additional steps of purification. The ergothioneine can be obtained by the following route, depicted in reaction scheme as follows:
As shown in the scheme above, it includes four successive steps:
Another aspect of the invention is a composition comprising a mixture of L-ergothioneine and D-ergothioneine, or a physiologically acceptable salt thereof, which can be prepared using the chemical synthesis method according to the present invention. This composition possesses broad applications in treating disease, cosmetic application, or nutritional supplement.
As used herein, the term “or” is meant to include both “and” and “or”. In other words, the term “or” may also be replaced with “and/or.”
As used herein, the singular forms “a,” “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.
As used herein, the term “at least” followed by a number is used to denote the start of a range beginning with that number.
As used herein, the term “physiologically acceptable” is taken to designate what is generally safe, non-toxic and neither biologically nor otherwise undesirable and which is acceptable for pharmaceutical, cosmetic or food (human or animal) use, in particular food. “Physiologically acceptable salts” of a compound is taken to designate salts that are physiologically acceptable, as defined above, and which have the desired activity (pharmacological, cosmetic or food) of the parent compound.
As used herein, the term “tautomer” or “tautomeric form” refers to structural isomers of different energies which are interconvertible via a low energy barrier. The different tautomer of a compound is generally interconvertible and present in equilibrium, in solution, in proportions that can vary according to the solvent used, the temperature, or even the pH. Within the framework of the invention, ergothioneine obtained from the present invention can be present as a tautomer between its thiol and thione forms.
Structure of L-ergothioneine (thione-thiol tarutomers) is shown below. It exists predominantly in the thione form at physiological pH.
As used herein, the term “optical isomer” or “optical form” refers to any of the various stereo isomeric configurations which may exist for a given compound of the present invention and includes geometric isomers. For example, naturally occurring alanine is the right-hand structure, and the way the groups are arranged around the central carbon atom is known as an L-configuration. The other configuration is known as D-configuration.
As used herein, the term “enantiomers” refers to stereo isomers that are mirror images of each other, but not superimposable. A mixture containing equal quantities of two individual enantiomer forms of opposite chirality is designated as “racemic mixture”.
Synthetic methodologies illustrated herein are intended to exemplify the applicable chemistry through the use of specific examples and are not indicative of the scope of the disclosure.
All reagents used in the Examples were obtained from commercial suppliers without further purification.
Step (a): in a first solvent, reacting histidine (compound I) with a protective reagent I and a protective agent II in the presence of a base, thereby obtaining a compound (II), wherein the histidine is either in a pure optical form (e.g., L-form or D-form), or a mixture of both forms;
To achieve a better yield of the desired product, reaction conditions of step (a), including solvent, protective reagents and base, were screened. The obtained products were analyzed by High Performance Liquid Chromatography (HPLC), and results are shown in Table 1.
The results showed that:
Step (b): in a second solvent, reacting the compound (II) with an alkylation reagent, thereby obtaining a compound (III);
For step (b), reaction conditions, including methylation reagents, solvent and reaction temperature were screened for a higher yield of desired product (i.e. Compound III). The yield was analyzed by HPLC, and results are listed in Table 2 below.
Results showed that:
Step (c): in a third solvent, hydrolyzing the compound (III) in the presence of an acid, obtaining a compound (IV);
For step (c), the reaction conditions, including the solvent, acid and reaction temperature were screened for a higher yield of desired product. The results were analyzed by HPLC, and results are listed in Table 3 below.
The results showed that:
1H NMR (400 MHZ, CD3OD-d6) δ 7.17-7.44 (m, 16H), 6.87 (s, 1H), 3.84 (dd, 1H), 3.17 (dd, 1H), 2.98 (dd, 1H).
1H NMR (400 MHZ, CD3OD-d6) δ 7.16-7.44 (m, 16H), 6.91 (s, 1H), 3.89 (dd, 1H), 3.19-3.28 (m, 11H).
1H NMR (400 MHZ, D2O-d6) δ 7.58 (S, 1H), 6.87 (s, 1H), 3.79 (dd, 1H), 3.09-3.15 (m, 11H).
1H NMR (400 MHZ, D2O-d6) δ 6.72 (S, 1H), 3.83 (dd, 1H), 3.09-3.15 (m, 11H).
1H NMR (400 MHZ, CD3OD-d6) δ 7.18-7.42 (m, 6H), 6.87 (s, 1H), 3.84 (dd, 1H), 3.17 (dd, 1H), 2.98 (dd, 1H).
1H NMR (400 MHZ, CD3OD-d6) δ 7.16-7.44 (m, 11H), 6.91 (s, 1H), 3.89 (dd, 1H), 3.19-3.28 (m, 11H).
1H NMR (400 MHZ, D2O-d6) δ 7.58 (S, 1H), 6.87 (s, 1H), 3.79 (dd, 1H), 3.09-3.15 (m, 11H).
1H NMR (400 MHZ, D2O-d6) δ 6.72 (S, 1H), δ 6.86 (S, 1H), 3.83 (dd, 1H), 3.09-3.15 (m, 11H).
1H NMR (400 MHZ, CD3OD-d6) δ 7.18-7.42 (m, 6H), 6.87 (s, 1H), 6.45 (s, 2H), 3.84 (dd, 1H), 3.17 (dd, 1H), 2.98 (dd, 1H).
1H NMR (400 MHZ, CD3OD-d6) δ 7.12-7.2 (m, 6H), 6.91 (s, 1H), 6.45 (s, 2H), 3.89 (dd, 1H), 3.19-3.28 (m, 11H).
1H NMR (400 MHZ, D2O-d6) δ 7.58 (S, 1H), 6.87 (s, 1H), 3.79 (dd, 1H), 3.09-3.15 (m, 11H).
1H NMR (400 MHZ, D2O-d6) δ 6.72 (S, 1H), 3.83 (dd, 1H), 3.09-3.15 (m, 11H).
1H NMR (400 MHZ, CD3OD-d6) δ 7.17-7.44 (m, 16H), 6.87 (s, 1H), 3.84 (dd, 1H), 3.17 (dd, 1H), 2.98 (dd, 1H).
1H NMR (400 MHZ, CD3OD-d6) δ 7.16-7.44 (m, 16H), 6.91 (s, 1H), 3.89 (dd, 1H), 3.19-3.28 (m, 11H).
1H NMR (400 MHZ, D2O-d6) δ 7.58 (S, 1H), 6.87 (s, 1H), 3.79 (dd, 1H), 3.09-3.15 (m, 11H).
1H NMR (400 MHZ, D2O-d6) δ 6.72 (S, 1H), 3.83 (dd, 1H), 3.09-3.15 (m, 11H).
1H NMR (400 MHZ, CD3OD-d6) δ 7.17-7.44 (m, 16H), 6.87 (s, 1H), 3.84 (dd, 1H), 3.17 (dd, 1H), 2.98 (dd, 1H).
1H NMR (400 MHZ, CD3OD-d6) δ 7.16-7.44 (m, 16H), 6.91 (s, 1H), 3.89 (dd, 1H), 3.19-3.28 (m, 11H).
1H NMR (400 MHZ, D2O-d6) δ 7.58 (S, 1H), 6.87 (s, 1H), 3.79 (dd, 1H), 3.09-3.15 (m, 11H).
1H NMR (400 MHZ, D2O-d6) δ 6.72 (S, 1H), 3.83 (dd, 1H), 3.09-3.15 (m, 11H).
Although specific embodiments and examples of this invention have been illustrated herein, it will be appreciated by those skilled in the art that any modifications and variations can be made without departing from the spirit of the invention. The examples and illustrations above are not intended to limit the scope of this invention. Any combination of embodiments of this invention, along with any obvious extension or analogs, are within the scope of this invention. Further, it is intended that this invention encompass any arrangement, which is calculated to achieve that same purpose, and all such variations and modifications as fall within the scope of the appended claims.
All the features disclosed in this specification (including any accompanying claims, abstract and drawings) may be replaced by alternative features serving the same, equivalent, or similar purpose, unless expressly stated otherwise. Thus, unless expressly stated otherwise, each feature disclosed is one example of a generic series of equivalent or similar features.
It is to be understood that while the invention has been described in conjunction with the detailed description thereof and accompanying FIGURES, the foregoing description and accompanying FIGURES are only intended to illustrate, and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims. All publications referenced herein are incorporated by reference in their entireties.
This application is a continuation application of International Patent Application No. PCT/CN2022/088496, filed on Apr. 22, 2022, the contents of which are incorporated herein by reference in their entirety.
Number | Date | Country | |
---|---|---|---|
Parent | PCT/CN2022/088496 | Apr 2022 | WO |
Child | 18921672 | US |